Oncology

New data on leronlimab reveals striking long-term survival signals in heavily pretreated mTNBC patients, hinting at a new way to fight the disease.

New data reveals a targeted therapy can help patients with a rare, aggressive lung cancer even after their disease shows signs of worsening.

New real-world data on PEDMARK® suggests a breakthrough in preventing cisplatin-induced hearing loss for adults, a major step in cancer survivorship.

Verana Health's new AI-driven datasets offer an unprecedented end-to-end view of the patient journey, aiming to accelerate urologic cancer research.

A novel implant activating the body's own pathways could offer a safer, more effective alternative to traditional hormone therapies for breast cancer.

In memory of Brynne Coletti, a family's transformational $10M gift will create a new women's cancer program, bringing world-class care to Southwest Florida.

Pharma giant AbbVie raises its dividend, backed by robust financials and a powerful drug pipeline that signals a thriving post-Humira growth era.

An international team receives a major grant to use artificial intelligence to predict survival and treatment response, offering new hope for a deadly disease.

With new kits for complex cell models, Atrandi's semi-permeable capsules challenge market leaders by enabling multi-step workflows previously out of reach.

With two blockbuster cancer drugs driving record revenue, all eyes are on Syndax's upcoming earnings call for its 2026 outlook and growth strategy.

With a major €12.5M EU funding package, Step Pharma is fast-tracking dencatistat, a novel therapy targeting a key vulnerability in ovarian and endometrial cancers.

An international team, backed by a $2M grant from a global consortium and Microsoft, will use AI to personalize care for a long-overlooked disease.

Early data reveals a novel immunotherapy, STC-1010, may activate the immune system against a common, treatment-resistant form of colorectal cancer.

Flatiron Health launches a first-of-its-kind AI platform, merging data from 400,000 patients to revolutionize prostate cancer research and treatment.

A new cancer care company has tapped titans of medicine, policy, and patient advocacy to guide its mission of transforming treatment from the clinic to the home.

New head-to-head study results for POSLUMA PET imaging could redefine diagnostic clarity for prostate cancer, promising earlier and more precise detection.

As Jazz Pharmaceuticals preps for key investor talks, all eyes are on its blockbuster pipeline, revenue growth, and strategy to fend off competition.

With a $50.1M financing led by top investors, Coherus solidifies its strategic pivot from biosimilars to a pure-play oncology powerhouse.

Genmab posts record 2025 revenue, driven by cancer drug sales and a major acquisition, setting an ambitious, investment-heavy course for 2026.

Pioneering surgeon Dr. Gopal H. Badlani receives a top honor for his decades of work building sustainable urological care in underserved nations.